Ola Lindén
21 – 38 of 38
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2007
-
Mark
Parametric images of antibody pharmacokinetics based on serial quantitative whole-body imaging and blood sampling
(
- Contribution to journal › Article
-
Mark
Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread
(
- Contribution to journal › Article
-
Mark
Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.
(
- Contribution to journal › Article
- 2006
-
Mark
Clinical applications of newer radionuclide therapies
(
- Contribution to journal › Article
- 2005
-
Mark
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab.
(
- Contribution to journal › Article
-
Mark
Radioimmunoterapi ved non-Hodgkins lymfom
(
- Contribution to journal › Article
-
Mark
Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.
(
- Contribution to journal › Article
- 2004
-
Mark
Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab
(
- Contribution to journal › Letter
- 2003
-
Mark
Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients.
(
- Contribution to journal › Article
- 2002
-
Mark
Single tumor cell uptake and dosimetry of technetium-99m Fab ' anti-CD22 in low-grade B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
(
- Contribution to journal › Article
-
Mark
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
(
- Contribution to journal › Article
- 2001
-
Mark
Durable response to 90-yttrium-Epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule
(
- Contribution to journal › Article
- 1999
-
Mark
Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
(
- Contribution to journal › Article
- 1996
-
Mark
High-grade non-Hodgkin's lymphoma stage I. A retrospective study of treatment, outcome and prognostic factors in 213 patients
(
- Contribution to journal › Article
- 1988
-
Mark
Lymphocyte subpopulations and lymphokine production in children with constitutional aplastic anemia
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »